Board of Directors

Adrian Adams

Chairman of the Board

Mr. Adams has served as the Chairman of the AcelRx board of directors since February, 2013. Mr. Adams has been chief executive officer of Aralez Pharmaceuticals, formerly Pozen Inc., since June, 2015. Prior to this Mr. Adams served as president and chief executive officer of Auxilium Pharmaceuticals Inc. from December, 2011 until the acquisition of the company by Endo International PLC in February 2015. Prior to joining Auxilium, Mr. Adams served as chairman and chief executive officer of Neurologix, a Company focused on development of multiple innovative gene therapy development programs. Before Neurologix, Mr. Adams served as president and chief executive officer of Inspire Pharmaceuticals, Inc., where he oversaw the commercialization and development of prescription pharmaceutical products and led the company through a strategic acquisition by global pharmaceutical leader Merck & Co., Inc. in May 2011. Prior to Inspire, Mr. Adams served as president and chief executive officer of Sepracor Inc. from December 2006 until February 2010. Under his leadership, Sepracor conducted multiple strategic corporate development activities, including the in-licensing of seven products and out-licensing deals with two major pharmaceutical companies, prior to its acquisition by Dainippon Sumitomo Pharma Co. Prior to joining Sepracor, Mr. Adams was president and chief executive officer of Kos Pharmaceuticals, Inc. from 2002 until the acquisition of the company by Abbott Laboratories in December 2006. During his tenure he led the transformation of Kos into a fully integrated and profitable pharmaceutical company with annual revenues approaching $1 billion. Mr. Adams graduated from the Royal Institute of Chemistry at Salford University in the UK.

Mark G. Edwards

Bioscience Advisors Inc.

Mr. Edwards has served as a director on the AcelRx board since 2011. Mr. Edwards is managing director of Bioscience Advisors Inc., a biopharmaceutical consulting firm he founded in 2011. He also currently sits on the board of the California Institute for Biomedical Research (Calibr), based in La Jolla, CA. Previously, he was managing director and a principal of Deloitte Recap LLC, a wholly-owned subsidiary of Deloitte Touche Tohmatsu. Until its sale to Deloitte in 2008, Mr. Edwards was the managing director and founder of Recombinant Capital, Inc. (Recap), a consulting and database firm based in Walnut Creek, California. More than 100 biotechnology, pharmaceutical and service companies have retained Mr. Edwards to advise on biotech alliances and valuations over the past two decades. He has provided expert testimony in lawsuits involving reasonable royalties, transfer pricing and custom and practice in the biotechnology and pharmaceutical industries. Prior to founding Recap in 1988, Mr. Edwards was manager of business development at Chiron Corporation. He received his Bachelor of Arts and Master of Business Administration from Stanford University.

Stephen J. Hoffman, PhD, MD

Skyline Ventures

Dr. Hoffman has served as a director on the AcelRx board since February 2010. Dr. Hoffman has been a senior advisor to PDL BioPharma, Inc. since February of 2014. Prior to that, he served as a managing director at Skyline Ventures, a venture capital firm, from May 2007 until February of 2014. From January 2003 to March 2007, Dr. Hoffman was a general partner at TechnoVenture Management, a venture capital firm. Prior to that, he served as president, chief executive officer and a director of Allos Therapeutics, a biopharmaceutical company from 1994 to 2002, where he remained chairman of the board until its acquisition in 2012. From 1990 to 1994, Dr. Hoffman completed a fellowship in clinical oncology and a residency/fellowship in dermatology, both at the University of Colorado. Dr. Hoffman was the scientific founder of Somatogen Inc., a biotechnology company that was acquired in 1998 by Baxter International, Inc., a global medical products and services company, where he held the position of vice president of science and technology from 1987 until 1990. He serves on the board of directors of Concert Pharmaceuticals, Inc., a biotechnology company and Dicerna Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Hoffman holds a doctorate in bio-organic chemistry from Northwestern University and a medical degree from the University of Colorado School of Medicine.

Pamela P. Palmer, MD, PhD

Chief Medical Officer and Co-Founder

Dr. Palmer has served as a director on the AcelRx board and the Company’s chief medical officer since she co-founded the company in July 2005. Dr. Palmer gained extensive experience in the treatment of pain during her tenure as the director of the UCSF Pain Center for Advanced Research and Education (PainCARE) from 2005 to 2009, during which time the American Pain Society named the UCSF Pain Management Center and PainCARE jointly as one of only six centers of excellence nationwide. Prior to PainCARE, from 1999 to 2005, she was medical director of the UCSF Pain Management Center, which uses a comprehensive and multidisciplinary approach to treat patients with various stages and types of complex acute and chronic pain. From 1996 to 1999, Dr. Palmer worked as a faculty member at UCSF, where she conducted research on basic science mechanisms of pain transmission in her NIH-funded laboratory. In 1994 she co-founded Omeros Corporation, a biopharmaceutical company developing small-molecule and protein therapeutics aimed at improving pain management and clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Dr. Palmer remains a consultant to Omeros. Dr. Palmer received a medical degree and a doctorate in neuroscience at Stanford University, and continued on to the University of California, San Francisco for her anesthesia residency. She has an undergraduate degree in electrical engineering. Dr. Palmer is certified in anesthesiology and pain medicine by the American Board of Anesthesiology.

Howard B. Rosen

Chief Executive Officer

Mr. Rosen has served on the AcelRx board since 2008 and brings more than 25 years of experience in pharmaceutical and biotechnology leadership and strategy to AcelRx. Previously, he was vice president, commercial strategy at Gilead Sciences, Inc. from 2004 to 2008, where his responsibilities included strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead's overall portfolio and business planning. Prior to joining Gilead, Mr. Rosen was president of ALZA Corporation where he was responsible for all aspects of managing ALZA as an independent 1000-person operating company within the Johnson & Johnson Family of Companies. Previously at ALZA as vice president, product development, he was responsible for product development activities, portfolio management and corporate and new product planning. Over his 10 years at ALZA, Mr. Rosen also had responsibilities for mergers and acquisitions, R&D planning and technology ventures. Prior to joining ALZA, Mr. Rosen managed the west coast practice of Integral, Inc., was director, corporate development at GenPharm International, Inc. and was a consultant in the San Francisco office of McKinsey & Co. Mr. Rosen serves on the board of directors of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Entrega, Inc., Kala Pharmaceuticals, Inc., and ALCOBRA, LTD (NASDAQ: ADHD), where he has served as chairman since 2014. Previously he was a member of the boards of directors of ALDEA Pharmaceuticals, Inc., CNS Therapeutics, Inc., CoTherix, Inc., NTF Therapeutics, Inc., PaxVax, Inc., Pharsight Corporation, and Pearl Therapeutics, Inc., where he served as interim president and chief executive officer from June 2010 to March 2011. Mr. Rosen received a Master of Business Administration from the Stanford Graduate School of Business, where he graduated first in his class as the Henry Ford II Scholar. Mr. Rosen has a Master of Science in chemical engineering from MIT and he graduated with distinction from Stanford University with a Bachelor of Science in chemical engineering. Mr. Rosen was elected to the National Academy of Engineering in 2005.

Mark Wan

Three Arch Partners

Mr. Wan has served as a director on the AcelRx board since August 2006. Mr. Wan is a founding managing director of Causeway Media Partners. He is also a founding general partner of Three Arch Partners. Prior to co-founding Three Arch Partners in 1993, Mr. Wan was a general partner at Brentwood Associates, a private equity firm. Mr. Wan holds a Bachelor of Science in engineering and a Bachelor of Arts in economics from Yale University and a Master of Business Administration from the Stanford Graduate School of Business.

Dr. Richard Afable

Covenant Health Network

Dr. Afable has served as a director on the AcelRx board since 2013. Dr. Afable is the chief executive officer of St. Joseph Hoag Health, based in Irvine, California, a non-profit healthcare delivery system formed through the affiliation of Hoag Memorial Hospital Presbyterian and St. Joseph Health System in 2013. The network includes seven hospitals, an expansive physician network, and more than 50 outpatient and urgent care facilities in southern California. Dr. Afable's prior professional experience includes affiliations with managerial and patient oversight responsibility with Catholic Health East, Preferred Physician Partners, LLC, Catholic Healthcare Partners, and Wake Forest University Bowman Gray School of Medicine. He earned a Bachelor of Science in biology, a medical degree from Loyola University of Chicago, and a Master of Public Health from the University of Illinois at Chicago.